Separately, Beaufort Securities reiterated a buy rating on shares of Hutchison China MediTech Limited in a report on Tuesday, November 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $18.33.
Shares of Hutchison China MediTech Limited (NASDAQ:HCM) opened at 13.53 on Tuesday. The firm has a 50-day moving average of $13.84 and a 200-day moving average of $12.95. Hutchison China MediTech Limited has a one year low of $9.80 and a one year high of $16.06. The stock’s market cap is $1.64 billion.
“Hutchison China MediTech Limited (HCM) Given a $20.00 Price Target at Canaccord Genuity” was originally posted by sleekmoney and is owned by of sleekmoney. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The correct version of this article can be viewed at http://sleekmoney.com/hutchison-china-meditech-limited-hcm-given-a-20-00-price-target-at-canaccord-genuity/1662189.html.
Several large investors have recently bought and sold shares of HCM. GRATRY & Co LLC acquired a new stake in Hutchison China MediTech Limited during the second quarter valued at approximately $157,000. Folger Hill Asset Management LP acquired a new stake in Hutchison China MediTech Limited during the second quarter valued at approximately $1,130,000. Matthews International Capital Management LLC acquired a new stake in Hutchison China MediTech Limited during the fourth quarter valued at approximately $1,376,000. Baillie Gifford & Co. raised its stake in Hutchison China MediTech Limited by 0.5% in the fourth quarter. Baillie Gifford & Co. now owns 153,703 shares of the company’s stock valued at $2,086,000 after buying an additional 777 shares in the last quarter. Finally, Schroder Investment Management Group raised its stake in Hutchison China MediTech Limited by 49.9% in the third quarter. Schroder Investment Management Group now owns 624,543 shares of the company’s stock valued at $7,457,000 after buying an additional 208,006 shares in the last quarter. Institutional investors and hedge funds own 3.64% of the company’s stock.
Hutchison China MediTech Limited Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/hutchison-china-meditech-limited-hcm-given-a-20-00-price-target-at-canaccord-genuity/1662189.html
Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.